Back to Search Start Over

Long-term Management of Panuveitis and Choroidal Mass Associated with Rosai Dorfman Disease with Pegylated Interferon.

Authors :
Kim L
Bavinger JC
Shantha JG
Costarides A
Grossniklaus HE
Yeh S
Source :
Ocular immunology and inflammation [Ocul Immunol Inflamm] 2022 Jul; Vol. 30 (5), pp. 1078-1082. Date of Electronic Publication: 2021 Mar 08.
Publication Year :
2022

Abstract

Purpose: To present a patient with Rosai-Dorfman Disease (RDD), a histiocytic proliferative disorder typified by lymphadenopathy with rare ocular manifestations, who developed panuveitis that responded to pegylated interferon.<br />Methods: Descriptive case report of a patient with RDD with multi-organ involvement including ocular manifestations including bilateral panuveitis with choroidal masses.<br />Results: A 54-year-old African American woman with known systemic RDD of the breast, lung, and gastrointestinal tract presented with panuveitis with choroidal masses in both eyes. Her systemic and ocular disease initially responded well to oral and topical steroid therapy. Later, however, her systemic disease progressed with multiple muscular and bony lesions. Systemic therapy was switched to pegylated interferon, a cytokine with antiviral, antitumor and immunomodulatory activity. After 14 months of therapy with pegylated interferon, the patient's systemic and ocular disease stabilized.<br />Conclusion: Rosai-Dorfman disease may be complicated by panuveitis and choroidal masses that may respond to pegylated interferon with stabilization of systemic and ocular manifestations. A multi-disciplinary approach is essential given the unique diagnostic and management challenges of RDD.

Details

Language :
English
ISSN :
1744-5078
Volume :
30
Issue :
5
Database :
MEDLINE
Journal :
Ocular immunology and inflammation
Publication Type :
Academic Journal
Accession number :
33683183
Full Text :
https://doi.org/10.1080/09273948.2020.1867190